Summary
Uterine leiomyosarcomas are rare tumours and the results of treatment of advanced disease are poor. Ifosfamide and Adriamycin are both known to be active drugs in soft-tissue sarcomas. We present our experience using ifosfamide alone and in combination with adriamycin in advanced or recurrent uterine leiomyosarcomas. Ifosfamide alone was given as a 24-h infusion at doses ranging from 5 to 7.5 g/m2, with mesna rescue. In the combination regimen, ifosfamide was given at a dose of 5 g/m2 and Adriamycin, at a dose of 40 or 60 mg/m2. Ten patients were treated with ifosfamide alone, with only one partial response lasting 6 months. In all, 11 patients were treated with ifosfamide and Adriamycin, which resulted in 1 complete response that lasted 11 months. Although many of the patients had extensive disease and some had undergone prior treatment with other chemotherapy, ifosfamide would appear to have only modest activity at the dose and schedule used.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bramwell VHC, Mouridsen HT, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud M, Thomas D, Sylvester R, Van Oosterom A (1987) Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adults soft tissue sarcomas. Eur J Cancer Clin Oncol 23: 311
Hannigan EV, Freedman RS, Elder KW, Rutledge FN (1983) Treatment of advanced uterine sarcoma with vincristine, actinomycin D, and cyclophosphamide Gynecol Oncol 15: 224
Marchese MJ, Liskow AS, Crum CP, McCaffrey RM, Frick HC (1984) Uterine sarcomas: a clinicopathologic study, 1965–1981. Gynecol Oncol 18: 299
Meanwell CA, Blake AE, Kelley KA, Honigsberger L, Blackledge G (1986) Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol 22: 815
Norris HJ, Zaloudek CJ (1982) Mesenchymal tumors of the uterus. In: Pathology of the female genital tract, 2nd edn. Springer, Berlin Heidelberg New York, p 352
Omura GA, Mamor FJ, Blessing JA, Sedlacke TV, Thigpen JT, Creasman WT, Zaino RJ (1983) A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer 52: 626
Salazar OM, Bonfiglio TA, Patten SF, Keller, BE, Feldstein M, Dunne ME, Rudolph J (1978) Uterine sarcomas: natural history, treatment and prognosis. Cancer 42: 1152
Salazar OM, Bonfiglio TA, Patten SF, Keller BE, Feldstein ML, Dunne ME, Rudolph JH (1978) Uterine sarcomas: analysis of failures with special emphasis on the use of adjuvant radiation therapy. Cancer 42: 1161
Shimm DS, Bell DA, Fuller AF, Bowling MC, Orlow EL, Munzenrider JE, Nelson JH, Ingersoll FM, Nikrui N, Donovan J (1984) Sarcomas of the uterine corpus: prognostic factors and treatment. Radiother Oncol 2: 201
Slayton RE, Blessing JA, Angel C, Berman M (1987) Phase II trial of etoposide in the management of advanced and recurrent leiomyosarcoma of the uterus: a Gynecologic Oncology Group Study. Cancer Treat Rep 71: 1303
Stuart-Harris RC, Harper PG, Parsons CA, Kaye SB, Mooney CA, Gowing NF, Wiltshaw E (1983) High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma. Cancer Chemother Pharmacol 11: 69
Wiltshaw E, Westbury G, Harmer C, McKinna A, Fisher C (1986) Ifosfamide plus mesna with and without Adriamycin in soft-tissue sarcoma. Cancer Chemother Pharmacol 18 [Suppl 2]: 10
World Health Organization (1979) WHO handbook for reporting results of cancer treatment. Offset publication 48. WHO, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hawkins, R.E., Wiltshaw, E. & Mansi, J.L. Ifosfamide with and without Adriamycin in advanced uterine leiomyosarcoma. Cancer Chemother. Pharmacol. 26 (Suppl 1), S26–S29 (1990). https://doi.org/10.1007/BF00685412
Issue Date:
DOI: https://doi.org/10.1007/BF00685412